Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer1
- 1 November 2001
- journal article
- clinical trial
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 51 (4) , 974-981
- https://doi.org/10.1016/s0360-3016(01)01737-0
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Radiosensitization produced in vivo by once- vs. twice-weekly 2′2′-difluoro-2′-deoxycytidine (gemcitabine)International Journal of Radiation Oncology*Biology*Physics, 2000
- Phase I Trial of Twice-Weekly Gemcitabine and Concurrent Radiation in Patients With Advanced Pancreatic CancerJournal of Clinical Oncology, 1999
- Combined modality therapy for stage II and stage III pancreatic carcinoma.Journal of Clinical Oncology, 1997
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidineInternational Journal of Radiation Oncology*Biology*Physics, 1996
- No standard treatment is available for advanced pancreatic cancerEuropean Journal Of Cancer, 1995
- Clinical and preclinical activity of 2′,2′- difluorodeoxycytidine (gemcitabine)Cancer Treatment Reviews, 1993
- Combined modality treatment of localized unresectable adenocarcinoma of the pancreasInternational Journal of Radiation Oncology*Biology*Physics, 1988
- Pancreatic CancerArchives of Surgery, 1985
- Radiotherapy of unresectable pancreatic carcinoma: A six year experience with 104 patientsInternational Journal of Radiation Oncology*Biology*Physics, 1981